Elekta AB stock (SE0000163628): focus on recent earnings and oncology demand

Elekta AB has recently updated investors on its financial performance and outlook, highlighting demand trends in radiation therapy and software for cancer care. The stock remains of interest for US investors following the latest quarterly results and guidance.

Elekta AB, a Sweden-based specialist in radiation therapy and oncology software, has been in focus after its recent quarterly earnings update and outlook discussion, which gave investors new data points on order growth, profitability and cash flow. The company’s latest report underlined ongoing demand for linear accelerators and associated software, as well as the impact of currency movements and cost measures on margins, according to information published in its investor materials and press releases from early 2025 and late 2024. These disclosures provide a fresh basis for assessing the stock for global investors, including those in the United States, who follow the medical technology and cancer care space via international listings and depositary receipts, as reported in company filings and financial news coverage.

As of: 05/20/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Elekta
• Sector/industry: Medical technology / radiation oncology
• Headquarters/country: Stockholm, Sweden
• Core markets: Cancer treatment centers and hospitals worldwide
• Key revenue drivers: Linear accelerators, radiosurgery systems, oncology software and service contracts
• Home exchange/listing venue: Nasdaq Stockholm (ticker commonly quoted as EKTA B)
• Trading currency: Swedish krona (SEK)

Elekta AB: core business model

Elekta AB develops and sells equipment and software used in radiation therapy and radiosurgery for cancer and brain disorders. The portfolio spans linear accelerators, stereotactic systems and planning software that help hospitals deliver targeted radiation treatments. The company generates revenue not only from initial equipment sales but also from long-term service contracts, upgrades and software licenses, according to product descriptions and investor presentations available on its investor relations site and in recent company reports.

In addition to hardware and software, Elekta AB emphasizes clinical workflow and connectivity, offering tools that integrate imaging, treatment planning and delivery. This model creates an installed base that can generate recurring revenue over many years as customers renew service contracts and adopt new applications. The company’s strategy, as outlined in its capital markets and quarterly materials, aims to capture value from the complete treatment pathway from diagnosis to follow-up, according to documents published on its website and referenced by financial media in 2024 and 2025.

Geographically, Elekta AB serves customers in Europe, North America, Asia-Pacific and emerging markets, with a notable presence in the United States through cancer centers and academic hospitals that deploy its radiation therapy systems. The firm often highlights growth opportunities in underpenetrated markets where access to advanced radiation equipment remains limited, while also competing in replacement and upgrade cycles in more mature regions. These dynamics have been discussed in recent earnings calls and investor presentations, which stressed the importance of backlog development and installation capacity for future revenue.

Main revenue and product drivers for Elekta AB

The main revenue drivers for Elekta AB are sales of linear accelerators and advanced radiosurgery systems such as those used for stereotactic treatments, along with associated treatment planning software and oncology information systems. New system orders contribute to the backlog, which then converts to revenue as installations are completed. Service and maintenance contracts tied to the installed base provide recurring income and can help stabilize cash flow even when capital equipment cycles are uneven, according to the company’s earnings materials published alongside its recent quarterly results and reported by financial news outlets in 2024 and 2025.

Product innovation is another central driver, with Elekta AB investing in image-guided radiation therapy, adaptive workflows and cloud-connected software to improve precision and efficiency. The company has emphasized the role of artificial intelligence–assisted planning tools and integrated software platforms to support clinicians, building on research and development spending highlighted in its annual and interim reports. These innovations are intended to differentiate its offerings in competitive tenders and to support premium pricing in certain segments, according to commentary in results presentations and industry coverage by healthcare technology media during 2024.

Beyond technology, Elekta AB’s revenue is influenced by healthcare funding, reimbursement policies and hospital capital budgets, especially in key markets such as the United States and Western Europe. When macroeconomic conditions and government budgets are supportive, cancer centers may accelerate equipment replacement and expansion projects, helping order growth. Conversely, delays in tender decisions or supply chain disruptions can impact the timing of revenue recognition, a theme the company has discussed in recent quarters as it navigated logistics challenges and inflationary pressures. These factors have been mentioned in management remarks and summarized by financial media following earnings releases over the past year.

Industry trends and competitive position

Radiation therapy remains a core component of cancer care, and global demand for advanced treatment systems is influenced by demographic trends such as aging populations and rising cancer incidence. Industry analyses from market research firms in 2023 and 2024 described mid-single-digit to high-single-digit annual growth in radiation oncology equipment markets, driven by equipment upgrades and increased adoption in emerging regions. Within this environment, Elekta AB competes with large international peers offering linear accelerators and integrated oncology platforms, and the company’s share of tenders can be affected by product features, pricing, service presence and financing solutions.

Recent industry commentary has also highlighted the shift toward more precise and hypofractionated treatments, which require accurate targeting and robust imaging. Elekta AB’s strategic focus on stereotactic radiosurgery, advanced imaging integration and software connectivity aligns with these trends, according to its product launch materials and investor communications during 2024 and early 2025. As hospitals seek to treat more patients efficiently while maintaining quality, workflow optimization and interoperability with hospital IT systems become additional differentiators. Elekta AB has responded by emphasizing open standards and integrations with other clinical systems, as noted in its product documentation and conference presentations.

From a competitive standpoint, Elekta AB’s presence in key regions such as North America, Europe and Asia-Pacific allows it to participate in large public and private tenders, while its installed base creates a foundation for recurring service revenue. Nonetheless, the company operates in a concentrated industry where a few major vendors contest most large contracts, and pricing pressures can emerge, particularly when public tenders place a high weight on upfront cost. These factors have been discussed by industry observers and analysts in 2024 and 2025, and they remain relevant for investors evaluating long-term margin potential and the pace of product innovation.

Why Elekta AB matters for US investors

For US investors, Elekta AB offers exposure to the global radiation oncology market, a niche but strategically important segment within medical technology. Although the stock’s primary listing is on Nasdaq Stockholm and trades in Swedish krona, many international investors access it through global trading platforms or via custodial arrangements that allow exposure to Swedish equities. The company generates a meaningful portion of its revenue from North America, including the United States, where cancer centers and hospital systems represent significant reference customers, according to regional breakdowns provided in recent annual and interim reports during 2024.

US investors monitoring healthcare infrastructure and cancer care demand may view Elekta AB as a way to participate in long-term trends around oncology treatment and technology upgrades. Policy changes, reimbursement frameworks and capital spending decisions in the United States can influence the pace of equipment orders and service revenue, making the company indirectly sensitive to US healthcare cycles despite its European domicile. Financial media have noted this link when discussing the performance of international medtech companies during reporting seasons in 2024 and 2025, particularly when US hospital spending conditions were a topic on earnings calls.

Currency movements are another consideration for US-based holders, because the stock is priced in Swedish krona and reported figures are in that currency. Fluctuations in SEK versus the US dollar can affect translated returns, and Elekta AB’s financial disclosures regularly discuss how exchange rates impact reported sales and profit. For investors used to US-listed healthcare stocks, these additional variables—currency and foreign regulatory environments—are part of the risk profile when considering exposure to a non-US medtech company active in the oncology field.

Conclusion

Elekta AB remains an established player in radiation oncology, with a business model built around advanced treatment systems, software and recurring service revenue. Recent earnings and outlook updates have underlined both structural demand from rising cancer incidence and shorter-term influences such as tender timing, supply chain factors and currency movements. For US investors, the stock provides international exposure to oncology infrastructure, with opportunities tied to innovation and emerging-market expansion, but also risks related to competition, healthcare budgets and foreign exchange. As always, the company’s upcoming results and product developments will be key to tracking whether it can sustain growth and improve profitability over time.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.